This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Amicus Therapeutics (FOLD) Stock Is Surging Today

NEW YORK (TheStreet) -- Amicus Therapeutics (FOLD) surged Tuesday after the company announced its lead drug migalastat was effective in treating patients with Fabry disease in a late-stage trial.

Amicus found the drug effective in patients after 12 months of treatment in the trial, which tested migalastat as a form of monotherapy in patients with Fabry disease, a disorder in which a fat called globotriaosylceramide builds up in the body's cells. The company also released positive 24-month data. 

"Today is a great day for Amicus and the Fabry community," said Chairman and CEO John F. Crowley in a statement. "Pending positive data from our second Phase 3 study we expect to meet with regulatory authorities to discuss these data and determine the fastest registration pathway for migalastat."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Must Read: Why MidSouth Bancorp (MSL) Stock Is Up Today

The stock was up 21.74% to $2.24 at 2:04 p.m.

FOLD Chart

FOLD data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FOLD $6.32 -7.70%
AAPL $111.40 0.56%
FB $92.77 -1.30%
GOOG $642.35 0.14%
TSLA $240.55 -2.30%


Chart of I:DJI
DOW 16,810.20 +33.77 0.20%
S&P 500 1,979.18 -7.87 -0.40%
NASDAQ 4,742.7060 -38.5580 -0.81%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs